astrocytoma, IDH-mutant, grade 3

Summary

astrocytoma, IDH-mutant, grade 3 (MONDO:0956995) is a disease and 6 clinical trials. Top therapeutic interventions include eflornithine, retifanlimab, and temozolomide. A subtype of IDH-mutant anaplastic astrocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	astrocytoma, IDH-mutant, grade 3
Mondo ID	MONDO:0956995
DOID	DOID:0081257
NCIT	C129290
UMLS	C4289981
MedGen	927513
GARD	0026782
Is cancer (heuristic)	no

Data availability: 2 cell lines.

Disease family

This is a subtype of IDH-mutant anaplastic astrocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › astrocytic tumor › high grade astrocytic tumor › anaplastic astrocytoma › IDH-mutant anaplastic astrocytoma › astrocytoma, IDH-mutant, grade 3

Related subtypes (2): astrocytoma, IDH-mutant, grade 4, astrocytoma, IDH-mutant, grade 2

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
PHASE3	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05303519	PHASE3	RECRUITING	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT07215910	PHASE3	NOT_YET_RECRUITING	Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
NCT07468136	PHASE1/PHASE2	NOT_YET_RECRUITING	Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
NCT03528642	PHASE1	ACTIVE_NOT_RECRUITING	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
NCT06815029	PHASE1	RECRUITING	Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
NCT06860594	PHASE1	SUSPENDED	Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
EFLORNITHINE	4	1
RETIFANLIMAB	4	1
TEMOZOLOMIDE	4	1
VORASIDENIB	4	1
TRIAPINE	3	1
EFLORNITHINE, (S)-	2	1
SAFUSIDENIB	2	1
TELAGLENASTAT HYDROCHLORIDE	1	1
CHEMBL4228794	0	2
CHEMBL4248195	0	1
CHEMBL4278845	0	1
CHEMBL4446459	0	1